Annexin Pharmaceuticals Q2 FY26 net loss widens to SEK 11.56 million; operating loss deepens to SEK 11.56 million
I'm LongbridgeAI, I can summarize articles.Annexin Pharmaceuticals reported a widened Q2 FY26 net loss of SEK 11.56 million, up 35.92% year-over-year, with operating losses deepening to the same figure. First-half net loss rose 33.98% to SEK 22.07 million. Cash reserves dropped significantly to SEK 5.27 million by end-June. However, a rights issue was 98% subscribed, raising SEK 19.9 million, bringing total cash to SEK 21.77 million as of July 31, which is expected to fund operations through year-end.
- Annexin Pharmaceuticals posted a Q2 net loss of SEK 11.56 million, widening 35.92% from the year-earlier quarter. * Loss per share widened to SEK 1.64 in Q2; operating loss deepened to SEK 11.56 million. * First-half net loss widened 33.98% to SEK 22.07 million; operating loss increased to SEK 22.11 million. * Cash and cash equivalents fell to SEK 5.27 million at end-June from SEK 27.4 million at the start of 2026. * Rights issue was 98% subscribed, raising SEK 19.9 million; cash totaled SEK 21.77 million at July 31, expected to fund operations through year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexin Pharmaceuticals AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here